The role of proteomics in plasma fractionation and quality control of plasma-derived therapeutic proteins

Blood Transfusion

Volumn 8, Issue SUPPL. 3, 2010, Pages

  Gaso Sokac, Dajana ^a   Josic, Djuro ^b  

^a JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^b BROWN UNIVERSITY   (United States)

Author keywords

Factor VIII; Plasma fractionation; Proteomics; Quality control

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CERULOPLASMIN; FETUIN A; HAPTOGLOBIN; HEMOPEXIN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN LAMBDA CHAIN; PEPTIDOGLYCAN RECOGNITION PROTEIN; PLASMA PROTEIN; PREALBUMIN; PROTHROMBIN COMPLEX; VITAMIN D BINDING PROTEIN; VON WILLEBRAND FACTOR;

AFFINITY CHROMATOGRAPHY; FRACTIONATION; GLYCOSYLATION; NUCLEOTIDE SEQUENCE; PLASMA; PROTEIN DEGRADATION; PROTEOMICS; QUALITY CONTROL; REVIEW;

BIOMEDICAL TECHNOLOGY; BLOOD PROTEINS; HUMANS; PLASMA; PROTEOMICS; QUALITY CONTROL;

EID: 78049359738     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.014S     Document Type: Review

References (29)

1. Thiele T, Steil L, Völker U, Greinacher A. Proteomics of blood-based therapeutics. Biodrugs 2007; 21: 179-193.
2. Burnouf T. Modern plasma fractionation. Trans Med Rev 2007; 21: 101-117.
3. Josic D, Hoffer L, Buchacher A. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitors protein C. J Chromatogr B 2003; 790: 183-197.
4. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: An overview. Transfusion Apher Sci 2006; 35: 83-90.
5. Josic D, Schulz P, Biesert L, et al. Issues in the development of medical products based on human plasma. J Chromatogr B 1994; 694: 253-264.
6. Kovac S, Yang X, Huang F, et al. Proteomics as a tool for optimization of human plasma protein separation. J Chromatogr A 2008; 1194: 38-47.
7. Lion N, Tissot J-D. Application of proteomics to hematology: the revolution is starting. Expert Rev Proteomics 2008; 5: 375-9.
8. Liumbruno G, D'Amici GM, Grazzini G, Zolla L. Transfusion medicine in the era of proteomics. J Proteomics 2008; 71: 34-45.
9. Yang X, Clifton J, Huang F, et al. Proteomic analysis for process development and control of therapeutic protein separation from human plasma. Electrophoresis 2009; 30: 1185-93.
10. Fortis F, Guerrier L, Areces L, et al. A new approach for the detection and identification of protein impurities using combinatorial solid phase ligand library. J Proteome Res 2006; 5: 2577-2585. (Pubitemid 44595160)
11. Plematl A, Demelbauer UM, Josic D, Rizzi A. Determination of the site-specific glycosylation in human plasma-derived antithrombin by IEF and capillary HPLC-ESI-MS/MS, Proteomics 2005; 5: 4025-33.
12. Clifton J, Huang F, Kovac S, et al. Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates, Electrophoresis 2009; 30: 3636-46.
13. Belgacem O, Stübiger G, Allmaier G, et al. Isolation of esterified fatty acids bound to serum albumin purified from human plasma and chracterised by MALDI mass spectrometry. Biologicals 2007; 35: 43-9.
14. Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma - aspects of yield and virus safety. Biotechnol J 2006; 1: 148-63.
15. Radoshevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010; 98; 12-28.
16. Buchacher A, Schluga P, Müllner J, et al. Anticomplementary activity of IVIG concentrates - important assay parameters and impact of IgG polymers, Vox Sang 2009; early view, DOI:10.1111/j.1423-0410.2009.01271.x.
17. Page M, Ling C, Dilger P, et al. Fragmentation of therapeutic human immunoglobulin preparations, Vox Sang 1995; 69: 183-94.
18. Stadler M, Gruber G, Kannicht C, et al. Characterization of novel high-purity, double virus inactivated von Willebrand factor and Factor VIII concentrate (®Wilate). Biologicals 2006; 34: 281-88. (Pubitemid 44781195)
19. Saenko EL, Anayeva N, Kouiavskaia D, et al. Molecular defects in coagulation factor VIII and their impact on factor VIII function. Vox Sang 2002; 83: 89-96. (Pubitemid 36807282)
20. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3: 1154-69.
21. Mazurier C, Poulle M, Samor B, et al. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004; 86: 100-104.
22. Josic D, Kannicht C, Löster K, et al. Vitronectin in clotting factor IX concentrates. Haemophilia 2001; 7: 250-257.
23. Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of highly purified human plasma factor IX. C therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-32.
24. Clifton J, Huang F, Gaso-Sokac D, et al. Use of proteomics for validation of the isolation process of clotting factor IX from human plasma. J Proteomics 2010; 73: 678-88.
25. Brigulla M, Thiele T, Scharf C, et al. Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates. Transfusion 2006; 46: 377-85.
26. Demelbauer UM, Plematl A, Josic D, et al. On the variation og glycosylation in human plasma derived antithrombin. J Chromatogr A 2005; 1080: 15-21.
27. Kolarich D, Turecek PL, Weber A, et al. Biochemical, molecular characterization, and glycoproteomic analyses of alpha-1-proteinase inhibitor products used for replacement therapy. Transfusion 2006; 46: 1959-77.
28. Mizon C, Héron A, Capon C, et al. Human pre-alpha-inhibitor: isolation from a by-product of industrial scale plasma fractionation and structural analysis of its H3 heavy chain. J Chromatogr B 1997; 692: 281-91.
29. Josic D, Brown MK, Huang F, et al. Proteomic characterization of inter-alpha inhibitor proteins from human plasma. Proteomics 2006; 6: 2874-85. (Pubitemid 43752047)